ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and various ophthalmic viscoelastic products (e.g., CoEase, AMVISC).
Key Developments: In February 2004, the company received FDA approval for ORTHOVISC and launched it in the U.S. via a licensing agreement with Ortho Biotech Products, L.P. (Johnson & Johnson). In July 2004, the company announced a new partnership with OrthoNeutrogena for cosmetic tissue augmentation products.

Key Financial Metrics

Balance Sheet Highlights (June 30, 2004):
- Total Assets: $50,670,000
- Total Liabilities: $23,840,000 (Includes $21.8M in deferred revenue)
- Stockholders' Equity: $26,830,000
- Accumulated Deficit: $(5,018,000)

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 88.7% in Q2 2004 and 85.1% YTD compared to 2003. Product revenue grew 72.3% in Q2, driven by the U.S. launch of ORTHOVISC and increased international sales.
• Profitability: The company transitioned from a net loss to net income. YTD 2004 net income of $8.55 million includes a one-time income tax benefit of $7.0 million resulting from the release of a valuation allowance against deferred tax assets.
• Liquidity: Cash and cash equivalents increased from $14.6 million at year-end 2003 to $33.5 million at June 30, 2004, primarily due to a $20 million milestone payment received from Ortho Biotech in February 2004.
• Deferred Revenue: Deferred revenue increased significantly to $21.8 million (from $2.2 million at year-end 2003) due to the deferral of the $20 million milestone payment, which is being recognized ratably over ten years.
• Operating Expenses: R&D expenses increased 73.6% in Q2 and 39.5% YTD due to clinical trials for INCERT-S and cosmetic tissue augmentation products. SG&A expenses increased 48.9% in Q2 due to personnel and professional fees.

Guidance, Outlook, and Risks

• Outlook: Management expects U.S. ORTHOVISC sales to remain relatively flat in the second half of 2004 as the launch continues. International ORTHOVISC sales are expected to grow. Ophthalmic product sales are expected to increase modestly for 2004.
• Partnership Risks: The agreement with Advanced Medical Optics (distributor for CoEase) is expected to terminate in July 2005 following their acquisition of Pfizer's surgical ophthalmology business, potentially reducing future ophthalmic revenue. The company relies heavily on a small number of customers; three customers accounted for 71.8% of product revenue YTD 2004.
• Regulatory Risks: Future success depends on FDA approvals for new products (INCERT, CTA). Delays or failures in clinical trials or regulatory approvals could materially harm the business.
• Accounting Policies: Revenue from the Bausch & Lomb agreement is subject to retroactive price adjustments based on annual unit volume, creating uncertainty in final revenue recognition.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the amortization schedule and assumptions for the $20 million Ortho Biotech milestone payment deferred over ten years.
• Customer Concentration: Assess the risk associated with reliance on three major customers (Bausch & Lomb, Ortho Biotech, Pharmaren/Biomeks) for over 70% of product revenue.
• One-Time Tax Benefit: Confirm the sustainability of profitability excluding the $7.0 million one-time tax benefit from the release of the valuation allowance.
• Contract Expirations: Monitor the status of the Advanced Medical Optics agreement expiring in 2005 and the Bausch & Lomb agreement expiring in 2007.
• Clinical Trial Progress: Track the enrollment and results of the pivotal clinical trials for INCERT-S and cosmetic tissue augmentation products.